Table 4.
Multivariable analysis of progression-free survival (PFS) and overall survival (OS).
| Characteristic | PFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Sex Female (vs. male) |
1.07 |
0.64–1.80 |
0.79 |
|||
| Cancer type (vs. others) Urothelial cancer Renal cell cancer Gastric cancer MSI-high solid tumors |
0.67 3.63 |
0.44–1.03 2.14–6.16 |
0.07 <0.01 |
1.37 0.28 3.06 0.23 |
0.80–2.35 0.14–0.57 1.65–5.66 0.03–1.71 |
0.25 <0.01 <0.01 0.15 |
| ECOG performance status ≥2 (vs. 0 or 1) |
2.17 |
1.22–3.86 |
<0.01 |
|||
| Neutrophil/lymphocyte ratio ≥5 (vs. <5) |
1.59 |
1.20–2.10 |
<0.01 |
1.93 |
1.42–2.62 |
<0.01 |
| Soluble markers sPD-1low/sPD-L1high (vs. others) |
1.62 |
1.03–2.58 |
0.04 |
1.86 |
1.06–3.26 |
0.03 |
HR, hazard ratio; CI, confidence interval; MSI, microsatellite instability; sPD-1, soluble programmed cell death–1; sPD-L1, soluble programmed cell death–ligand 1.